

WHO HIV policy adoption and implementation in countries as of January 2025


Global HIV, Hepatitis and STIs Programmes, Strategic Information Analysis & Use (WHO/HHS/SIA)


Service provision modalities included in the national policy on ART for adults, adolescents and children, global, 2025





Service provision modalities included in the national policy on ART for adults, adolescents and children, by WHO region, 2025









Service provision modalities included in the national policy on ART for adults, adolescents and children, by WHO region, 2025






Percentage of countries with integrated HIV and primary health care, 2025




Percentage of countries with integrated HIV and services for other diseases, 2025





Adoption of WHO recommendations on oral pre-exposure prophylaxis (PrEP) in national guidelines, January 2025


By January 2025, 150 of 162 reporting countries (91%) had already adopted WHO recommendations on pre-exposure prophylaxis (PrEP) in their national guidelines.





Uptake of national policies on dual HIV and syphilis rapid diagnostic tests, January 2025


By January 2025, 95 countries had adopted dual HIV and syphilis rapid diagnostic tests in their national policies. Nearly half of these countries (48%, 46 of 95) adopted them for both pregnant women and key populations.





National policy on HIV self-testing and implementation status, January 2025


By January 2025, 109 countries reported national policies supporting HIV self-testing, with four countries reporting introduction of Hepatitis C self-testing.





Adoption of TDF+3TC (or FTC) + dolutegravir (DTG) as the preferred first-line antiretroviral combination for treatment initiation in national guidelines for adults and adolescents living with HIV, January 2025


By January 2025, 125 countries (94% of 136 reporting countries) had adopted DTG as part of the preferred first-line antiretroviral therapy for adults and adolescents, a 108% increase from 60 countries in 2020, when this indicator was first introduced.





Adoption of TDF+3TC (or FTC)+dolutegravir (DTG) as an option for second-line antiretroviral combination for adults and adolescents living with HIV, January 2025


By January 2025, of 124 reporting countries, 100 (81%) reported adopted DTG as part of second-line antiretroviral therapy for adults and adolescents. This represents a 117% increase from the 46 countries in 2020.





Adoption of dolutegravir (DTG) regimens as the preferred treatment initiation option in national guidelines for all infants and children living with HIV, January 2025


By January 2025, DTG-containing regimens had been adopted as the preferred treatment initiation option for infants and children in 80% (97 of 122) of reporting countries. This represents a 177% increase from 35 countries in 2020.





National policy on routine viral load testing for monitoring antiretroviral therapy and level of implementation among adults and adolescents living with HIV, January 2025


By January 2025, routine viral load monitoring for adults and adolescents had been implemented countrywide in 72% (89 of 124) of reporting low- and middle-income countries; of the remainder, 49% (17 of 35) reported implementation in many (50–95%) treatment sites.





Policy to offer antiretroviral therapy initiation on the same day as HIV diagnosis, January 2025


By January 2025, a total of 108 countries had adopted WHO's recommendation to offer antiretroviral therapy initiation on the same day of HIV diagnosis (83% of 130 reporting countries), an increase of 59% from 68 countries in 2020.





National policies on frequency of antiretroviral therapy pick-up for people who are established on antiretroviral therapy, January 2025


By January 2025, of 149 reporting countries, 113 (76%) had adopted WHO's recommendation to reduce the frequency of antiretroviral therapy pick-up for people established on treatment. A three-monthly interval is most frequent (54%, 81 of 149), followed by six-monthly interval (20%, 30 of 149).





Adoption of the WHO 2021 recommendation to offer a package of interventions to everyone presenting with advanced HIV disease, January 2025


By January 2025, most of the reporting countries had adopted WHO's recommended package of care for advanced HIV disease: either full adoption (73%, 95 of 131) or partial adoption (17%, 22 of 131).





National policy promoting community delivery of antiretroviral therapy, January 2025

By January 2025, a national policy promoting community delivery of antiretroviral therapy (such as outside health facilities) was available in 54 countries (45% of 121 reporting countries), more than twice the 20 countries in 2020.





National plan for eliminating the vertical transmission of HIV and syphilis, January 2025

By January 2025, 72% of all reporting countries had national plans for eliminating the vertical transmission of both HIV and syphilis (95 of 132), most of which were integrated, and a further 17% had a plan for eliminating the vertical transmission of either HIV (9 countries) or syphilis (14 countries).

